April 2021

Study undertaken in Ultra-rare paediatric disease

Data to be drawn from a descriptive, retrospective, cross sectional burden of illness study design developed by HCD Economics and University of Chester A peer-review manuscript published on 7th January 2021, in the journal ‘Expert Review of Pharmacoeconomics and Outcomes Research’ (impact factor 2.032), reports on the study rationale and protocol of the PICTURE study. PFIC Burden of Illness: Quantifying the global socio-economic burden The PICTURE study will employ a study design developed by HCD Economics and University of Chester in 2014. Founded on the principle of Public and Patient Involvement and Engagement (PPIE), the methodology has generated real-world evidence that can inform and support advocacy for clinical implementation of new therapies including rare diseases.
Read More
March 2021

‘Collaboration is vital – especially in rare disease’ – Professor Keith Abrams, University of Leicester

Jamie O’Hara joined the panel of yesterday’s collaborative webinar (24th Mach 2021), entitled ‘Economic Modelling in Rare Diseases’. The panel involved three leading academic centres, University of Leicester, York and Sheffield, digital research organisation Vitaccess, and leading health economic organisations Source Health Economics and HCD Economics. Jamie participated alongside panellists; Professor Keith Abrams, Professor John Brazier, Dr Jill Carlton, Josie Godfrey, Dr Mark Larkin and Juliet Mumby-Croft.
Read More
March 2021

HCD Economics launches 2021 NMD real world evidence initiative

Combining our commitment to the rare disease community with our established leadership in patient and public engagement led research (PPIE), HCD Economics is announcing a 2021 commitment to identify and undertake research intended to build a repository of real-world evidence (RWE) that can be applied to NMD community evidence-based advocacy initiatives and other programmes. The commitment is to invest and develop partnerships for a RWE programme to support access for NMD patients to new and emerging novel therapies in the treatment and management of NMD.
Read More
March 2021

HCD Economics plays a role in informing the future of decision making in NASH

The coreNASH: Multi- stakeholder Consensus on Core Outcomes for Decision Making About Nonalcoholic Steatohepatitis Treatment has announced publication of the work of the coreNASH panel. Leonardo Ruiz-Casas, Principal Health Economist, at HCD Economics is a member of the panel. The paper is published in the American Association for the Study of Liver Disease Journal, Hepatology Communications. The paper is available now.
Read More
January 2021

Spanish Healthcare Policy challenged by new study

A new study has just been published in the Human Resources for Health Journal. Author and HCD Economics colleague, Dr. Idaira Rodriguez Santana, undertook the research as a PhD student studying at the UK Centre for Health Economics at University of York. The study concludes that a reform intended to enhance the professional and career prospects of Spanish medical students on graduation with respect to international graduates is flawed. The results identified that the reform led to a widening of the gender gap among Spanish medical specialists. Specifically the reform had the unintended consequence of reducing the probability of Spanish female doctors accessing highly demanded specialities thus exacerbating the gender gap.
Read More
January 2021

COVID-19 and Real World Evidence 2021 - a Transformation of European Healthcare

Even before the emergence of COVID-19, the significance of real world data to European health policy and programmes was growing – notably in the domain of patient-reported outcomes and their integration by healthcare decision makers into resource allocation decision making, typically undertaken by Health Technology Assessment agencies across Europe.
Read More
December 2020

ISPOR extends on-line event during December, HCD award winning research available now

The live Virtual ISPOR Europe 2020 was held 16 – 19 November. The event brought together a vibrant community of experts and thought leaders virtually to help shape the future of HEOR. ISPOR states ‘we looked at fundamental conventions around value, risk, rewards, and the role of public and private sectors to drive innovation, investments and extending progress to broader public health concerns.’ HCD Economics received two Gold research awards from ISPOR. The Gold award is in recognition of having achieved the top 10% of reviewer scores.
Read More
November 2020

19-11-2020 - GAIN study webinar, expert commentary and Q and A - ‘the main game….’

Professors Manuel Romero Gómez and Jörn M. Schattenberg, leading experts in liver disease and members of the HCD Economics Expert Reference Group for the GAIN study (Global Assessment of the Impact of NASH (Non-Alcoholic SteatoHepatitis), a socio-economic study), addressed a global audience of over 30 delegates in a webinar intended to share the design and results of the GAIN study (published in 2020 in JHEP Reports the companion Journal to the highly respected Journal of Hepatology) and provide a forum for a live Q and A session, open to all webinar delegates. In his opening remarks Manuel confirmed that GAIN was part of ‘the main game’ to improve the outcome of NASH patients.
Read More